Avatar Cognition

Name

Avatar Cognition

Legal name

AVATAR COGNITION BARCELONA SL

Website

https://avatarcognition.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Technology Licensing: Licensing Synthetic Cognition technology to revolutionize Translational Medicine. Technology integration with heterogeneous multi-omic sources.
2. Platform Subscriptions (Web, Docker, API Versions): Three-tier platform delivery: Web Version (basic users), Docker Version (controlled environment for data privacy), API Version (full access with source code).
3. Professional Services / Custom Solutions: Collaborative projects with biotech, pharma, and research partners including use case development and validation.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Avatar Cognition develops and licenses Synthetic Cognition, a patented Artificial General Intelligence algorithm implemented via the Synthetic Abstraction framework and Function-Representation model of computation. The technology is delivered as a Python-based platform in three tiers (Web, Docker, API Version) and is targeted at life sciences and translational medicine for multi-omic data analysis, biomarker discovery, mechanism discovery, and predictive modeling with full explainability from minimal training data.

Product overview

Avatar Cognition offers a unified AI technology platform built around Synthetic Cognition, their core AI engine implementing a novel cognition framework inspired by biological cognition. The platform consists of three core modules: The Embodiment (data interface), The Engine (computational core), and The API (Python-based user interface). Products are delivered through three platform tiers: Web Version (basic users), Docker Version (enterprise/data privacy), and API Version (advanced users with source code access). The platform provides predictive analytics, knowledge discovery, and autonomous agent capabilities for multi-omic and clinical data analysis, primarily targeting the life sciences and healthcare markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Synthetic Cognition Platform Patented Artificial General Intelligence algorithm implementing the Synthetic Abstraction framework based on the Function-Representation model of computation. Fully automated with no setup or parameters, using Sparse Distributed Representations and self-regulated parameters (spatial, temporal, conditioning, attentional focus) for traceable and interpretable learning. Designed for life sciences and translational medicine use cases including multi-omic data analysis, biomarker discovery, and explainable prediction.
• Synthetic Cognition - Web Version Simplest delivery tier of the Synthetic Cognition platform with an easy-to-use interface requiring only basic data science knowledge. Built over the Python API for basic training and testing operations, aimed at basic users.
• Synthetic Cognition - Docker Version More complete delivery tier of the Synthetic Cognition platform providing full API access in a controlled, secure Docker environment. Specifically suited for enterprise tasks requiring strict data privacy because the isolated container separates Synthetic Cognition from external access.
• Synthetic Cognition - API Version Most complete version of the Synthetic Cognition platform with unlimited API access and full source code availability. Suited for advanced users and enterprises requiring deep customization and integration of the patented cognition framework into their own systems.
• Synthetic Cognition Technology Licensing Licensing of the patented Synthetic Cognition technology to biotech, pharma, and research organizations for integration into translational medicine workflows, with multi-omic data analytics and customization support.
• Synthetic Cognition Custom Solutions and Collaborative Projects Professional services offering that engages partners in collaborative projects for use case development and validation of Synthetic Cognition across biotech, pharma, and research use cases such as HIV vaccine trials, immunotherapy response prediction, sepsis prediction, and gut microbiota studies.

Quantifiable outcome

• 0.934 Accuracy in breast cancer subtype classification (Luminal A/B, HER2, Triple-Neg) vs MVGNN score of 0.918
• +5 more outcomes

Named customers8 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature10 records

Partnerships

Eight partnerships are on record, tiered core and major.

• Aelix TherapeuticscoreStrategic or Co-development PartnerCollaboration for HIV therapeutic vaccine trial transcriptomic data analysis. Avatar Cognition applied Synthetic Cognition to analyze transcriptomic data from therapeutic vaccine trials.
• IrsiCaixacoreStrategic or Co-development PartnerResearch partnership for studying Gut Microbiota Link to Sexual Preference and HIV Infection. Applied Synthetic Cognition to analyze complex biological datasets.
• Vall d'Hebron Institute of Oncology (VHIO)coreStrategic or Co-development PartnerCollaboration on Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors research. Demonstrated technology capability in clinical oncology applications.
• Leading Research Institute in ImmunologymajorStrategic or Co-development PartnerAutomated Multi-Omic Discovery project extracting meaningful signals from small high-value cohort (n=10) by integrating Transcriptomics, Methylomics, and Microbiome data. System automatically harmonized heterogeneous data types without ad-hoc engineering.
• Clinical-Stage Biotech CompanymajorStrategic or Co-development PartnerCollaboration for understanding therapeutic vaccine efficacy in Phase 1 trial using longitudinal transcriptomics (time-series gene expression across 5 timepoints). Achieved simultaneous prediction of top vaccine responders and discovery of expression patterns involved in enhanced antiviral defense.
• Reference Center for Personalized OncologymajorStrategic or Co-development PartnerNon-invasive prediction project using approximately 100 radiomic features extracted from CT images for predicting immunotherapy response in solid tumors with strict data privacy constraints. Deployed on-site in one morning.
• Major Pediatric HospitalmajorStrategic or Co-development PartnerSepsis prediction project in highly unbalanced pediatric dataset where only 2% of cases were positive. Achieved 2nd place in global public competition (AUC 0.592), outperforming XGBoost models without needing synthetic data generation.
• Leading Microbial Genomics GroupmajorStrategic or Co-development PartnerHeterogeneous data integration project linking gut microbiota to viral infection and lifestyle factors. Integrated 274 diverse variables (clinical, dietary, blood variables with bacterial counts) to discover 5 new bacterial correlations previously unknown to researchers.

Scale indicators3 records

Recent moves2 records

Expansion highlights5 records

Direct peers

• Owkin: AI-for-life-sciences platform that builds predictive models on multi-omic and clinical data for hospitals, biotech and pharma. Closely comparable to Avatar Cognition in target customer (research institutions, pharma), data modalities (multi-omics, imaging) and explainable-AI positioning.
• Insitro: Machine-learning-driven drug discovery company combining high-throughput biology with predictive models for pharma partners. Comparable to Avatar Cognition's biotech/pharma GTM and focus on predictive modeling from biological data.
• Recursion Pharmaceuticals: AI-native drug discovery company applying machine learning to high-dimensional biological data to identify novel therapeutics. Comparable target customers (pharma partnerships), data-driven biology approach, and predictive modeling on biological datasets.
• Tempus Labs: AI and data platform for precision medicine that integrates multi-omic, clinical and imaging data to support oncology and other therapeutic decisions. Strongly comparable multi-omic + clinical data focus and enterprise health-system GTM.
• BenevolentAI: AI platform for drug discovery and biomedical research, applying knowledge graphs and ML to accelerate target identification for pharma. Comparable in applying AI to biomedical data for pharma research customers.
• Deep Genomics: AI platform purpose-built for genomic medicine and oligonucleotide drug discovery. Comparable in AI-driven prediction on biological data and pharma/biotech commercial motion.

Broad incumbents

• Schrödinger: Established computational chemistry and biology platform serving pharma and biotech with predictive modeling across molecules and materials. Comparable life-sciences predictive-AI category but operates as a broader incumbent with a much larger portfolio.
• DataRobot: Enterprise AI/ML platform providing automated model building, deployment and governance. Comparable as a general-purpose predictive-AI platform but does not specialize in life sciences or omics data.
• H2O.ai: Provider of an open-source and enterprise AI/ML platform for predictive analytics, including healthcare and life sciences customers. Comparable horizontal predictive-AI category but not specialized in multi-omic data.

Emerging players

• AbCellera: AI-driven antibody discovery company using high-throughput biology and ML to identify therapeutic candidates for partners. Partially comparable — biotech GTM and AI-on-biology overlap, but narrower therapeutic modality (antibodies only).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AvatarCognition
• LinkedInlinkedin.com/company/avatarcognition

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avatar Cognition